company background image
BRTX logo

BioRestorative Therapies NasdaqCM:BRTX Stock Report

Last Price

US$1.38

Market Cap

US$9.1m

7D

3.8%

1Y

-61.2%

Updated

28 Mar, 2024

Data

Company Financials +

BioRestorative Therapies, Inc.

NasdaqCM:BRTX Stock Report

Market Cap: US$9.1m

BRTX Stock Overview

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells.

BRTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BioRestorative Therapies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioRestorative Therapies
Historical stock prices
Current Share PriceUS$1.38
52 Week HighUS$7.13
52 Week LowUS$1.20
Beta61.22
1 Month Change7.81%
3 Month Change-20.69%
1 Year Change-61.24%
3 Year Change-97.16%
5 Year Change-99.96%
Change since IPO-100.00%

Recent News & Updates

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

Shareholder Returns

BRTXUS BiotechsUS Market
7D3.8%0.9%0.2%
1Y-61.2%11.0%28.1%

Return vs Industry: BRTX underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BRTX underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BRTX's price volatile compared to industry and market?
BRTX volatility
BRTX Average Weekly Movement22.9%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BRTX's share price has been volatile over the past 3 months.

Volatility Over Time: BRTX's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199710Lance Alstodthttps://www.biorestorative.com

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company’s two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders.

BioRestorative Therapies, Inc. Fundamentals Summary

How do BioRestorative Therapies's earnings and revenue compare to its market cap?
BRTX fundamental statistics
Market capUS$9.13m
Earnings (TTM)-US$15.94m
Revenue (TTM)US$130.20k

69.5x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRTX income statement (TTM)
RevenueUS$130.20k
Cost of RevenueUS$0
Gross ProfitUS$130.20k
Other ExpensesUS$16.07m
Earnings-US$15.94m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.43
Gross Margin100.00%
Net Profit Margin-12,241.03%
Debt/Equity Ratio0%

How did BRTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.